Neuroblastoma (NB) is the most common pediatric neuroendocrine tumor, and it is characterized by a quite variable clinical course. We previously found a great variability in the expression of somatostatin receptor type 2 (sst2) in several human NB cell lines and primary tumors. In this report we investigated whether expression of sst2 is somehow related to clinical outcome. We performed a retrospective study on 54 patients with a maximum follow-up of 100 months. The concentration of specific messenger ribonucleic acid (mRNA) for sst2 was measured by competitive RT-PCR and validated, in a small subset of samples, by quantitative imaging of gene (in situ hybridization) and protein (immunohistochemistry) expression. We found that sst2 mRNA was variably expressed in all NB tumors (range, 2.5 x 10(5) to 8 x 10(9) molecules/microg RNA) with a relevant reduction in the more advanced stage (P < 0.01). Analysis of Kaplan-Meier curves indicated that sst2 expression is positively related to the overall (P < 0.0001) and event-free (P < 0.0001) survival. Expression of sst2 was negatively related to tumor stage (P < 0.02) and MYCN amplification (P < 0.001), a poor prognostic factor. However, the prognostic information derived from sst2 is apparently independent from MYCN amplification, as assessed by stratifying sst2 values according to MYCN. In addition, the expression of sst2 was the only significant prognostic factor (P < 0.02) when it was included in a multivariate model containing other well known prognostic factors such as age, stage, and MYCN amplification. Hence, we propose that sst2 expression represents a new prognostic marker for NB. The main clinical value of a quantitative measure of sst2 lies in its ability to detect patients at low risk, independently from other prognostic factor, including MYCN amplification.

译文

:神经母细胞瘤(NB)是最常见的小儿神经内分泌肿瘤,其特点是临床过程变化很大。我们先前发现生长抑素受体2型(sst2)在几种人NB细胞系和原发性肿瘤中的表达存在很大差异。在本报告中,我们调查了sst2的表达是否与临床结果相关。我们对54例患者进行了回顾性研究,最大随访时间为100个月。通过竞争性RT-PCR测量sst2的特定信使核糖核酸(mRNA)的浓度,并在一小部分样品中通过定量成像基因(原位杂交)和蛋白质(免疫组织化学)进行验证。我们发现sst2 mRNA在所有NB肿瘤中均可变表达(范围为2.5 x 10(5)至8 x 10(9)分子/ microg RNA),并且在更晚期阶段有相关的减少(P <0.01)。 Kaplan-Meier曲线的分析表明sst2表达与总体生存期(P <0.0001)和无事件生存期(P <0.0001)正相关。 sst2的表达与肿瘤分期(P <0.02)和MYCN扩增(P <0.001)呈负相关,这是不良的预后因素。但是,从sst2得出的预后信息显然与MYCN扩增无关,如通过根据MYCN分层sst2值所评估的。此外,当sst2的表达包含在包含其他众所周知的预后因素(例如年龄,阶段和MYCN扩增)的多变量模型中时,它是唯一的重要预后因素(P <0.02)。因此,我们建议sst2表达代表NB的新的预后标志物。定量检测sst2的主要临床价值在于其能够独立于其他预后因素(包括MYCN扩增)检测低危患者。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录